IP Library Granted Patent US 7,723,532
Granted Patent B2
US 7,723,532 · App. 11/552,095 · Granted May 25, 2010

Pharmaceutical compositions 3

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,723,532
App. No.
11/552,095
Granted
May 25, 2010
Kind
B2
Abstract

The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Claims (25)

1. A compound having the structure

wherein,

R 1 is —OH, an ester or an ether;

R 2 is —OH or an ether;

R 3 is —H, —OH, —F, —Br or an ester;

R 4 is —OH or an ester; and

R 5 is —CH 3 or —CH 2 OH.

2. The compound of claim 1 having the structure

3. The compound of claim 2 wherein R 1 is —OH or —OCH 3 .

4. The compound of claim 3 wherein R 4 is —OH or —O—C(O)—CH 3 .

5. The compound of claim 1 having the structure

6. The compound of claim 5 having the structure

7. A pharmaceutical formulation comprising one or more excipients and a compound having the structure

wherein,

R 1 , R 2 and R 4 independently are —OH, an ester or an ether;

R 3 is —H, —OH, a halogen, an ester or an ether; and

R 5 is —CH 3 or —CH 2 OH.

8. The pharmaceutical formulation of claim 7 wherein the compound has the structure

9. The pharmaceutical formulation of claim 7 wherein the compound has the structure

10. The pharmaceutical formulation of claim 7 wherein R 3 is —OH or an ester.

11. The pharmaceutical formulation of claim 8 wherein the compound has the structure

12. The pharmaceutical formulation of claim 11 wherein R 1 and R 2 independently are —OH or an ether.

13. The pharmaceutical formulation of claim 12 wherein R 4 is —OH or an ester and R 5 is —CH 3 .

14. The pharmaceutical formulation of claim 9 wherein the compound has the structure

15. The pharmaceutical formulation of claim 9 wherein R 1 is —OH or —OCH 3 , R 4 is —OH and R 5 is —CH 3 .

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057116/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057116/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057116/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2020
From: FRINCKE, JAMES MARTIN; READING, CHRISTOPHER L.; AHLEM, CLARENCE NATHANIEL
To: HOLLIS-EDEN PHARMACEUTICALS, INC.
Reel/Frame 053504/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2020
From: RESERVA, LLC
To: NEURMEDIX, INC.
Reel/Frame 053463/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2020
From: HARBOR DIVERSIFIED, INC.
To: HARBOR THERAPEUTICS, INC.
Reel/Frame 053449/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2020
From: HARBOR THERAPEUTICS, INC.
To: RESERVA, LLC
Reel/Frame 053451/0495 →
CHANGE OF NAME Recorded Nov 2, 2012
From: HARBOR BIOSCIENCES, INC.
To: HARBOR DIVERSIFIED, INC.
Reel/Frame 029227/0929 →
CHANGE OF NAME Recorded Mar 11, 2010
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 024066/0325 →